Traumakine Update

Faron Pharmaceuticals Oy (“Faron” or the “Company”)· €2.5 million loan guarantee from Finnvera to further expand IV IFN beta-1a manufacturing process · AGC Biologics selected as new commercial scale manufacturer · COVID-19 trials continue to investigate Traumakine treatment Company announcement, 18 August 2020 at 9.00 AM (EET)Insider information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today provides an update on manufacturing plans for Traumakine, its investigational intravenous (IV)